OPKO Health and Entera Bio to present GLP-2 analog poster at ESPEN Congress.

OPKO Health and Entera Bio announced their abstract "First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome" has been selected for poster presentation at the 47th ESPEN Congress in Prague, Czech Republic, September 13-16, 2025. The poster will display the oral GLP-2 tablet program, a long-acting GLP-2 agonist developed by OPKO and Entera's proprietary N-Tab technology for patients with short bowel syndrome and gastrointestinal mucosal inflammation.

OPKO Health (NASDAQ: OPK) and Entera Bio (NASDAQ: ENTX) have announced that their abstract titled "First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome" has been selected for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism (ESPEN) Congress, set to take place in Prague, Czech Republic, from September 13 to 16, 2025. The abstract will showcase an oral GLP-2 tablet program that combines OPKO's proprietary long-acting GLP-2 agonist with Entera's N-Tab™ technology, aiming to provide a more patient-friendly alternative to current injectable treatments.

Short bowel syndrome (SBS) is a rare and potentially life-threatening condition characterized by a significant loss of functional bowel mass, often resulting from congenital defects or intestinal resection. Approximately 30,000 patients across the US and EU are living with SBS, and current annual sales of GATTEX® (teduglutide), the only approved therapy for SBS, total roughly $800 million [1].

The oral GLP-2 tablet program, developed by OPKO and Entera, targets SBS patients and those with gastrointestinal mucosal inflammation and nutrient malabsorption. The program aims to improve treatment compliance and enable more personalized care by providing an oral alternative to GATTEX®, which currently requires daily subcutaneous injections. Miranda Toledano, Entera's Chief Executive Officer, commented, "Given the heterogeneity of patients with SBS and challenging compliance rates attributed to injectable GLP-2 therapy, we believe a daily tablet format may enable more personalized care of this peptide and individualize titration."

The poster presentation will be held on September 13, 2025, from 3:30 to 4:00 p.m. local time at the Forum Hall Foyer 3 during the ESPEN Congress. The abstract will provide insights into the potential benefits of an oral tablet format for SBS treatment, including improved compliance and personalized care.

References:
[1] https://www.stocktitan.net/news/OPK/opko-health-and-entera-bio-announce-abstract-on-pk-pd-of-oral-glp-2-ga55ls2wq624.html